Exploring clinical chemistry markers in amyotrophic lateral sclerosis: insights into survival and disease trajectories
Authors:
Open Access
- 12 December 2024
- journal article
- research article
- Published by Springer Nature in Journal of Neurology
- Vol. 272 (1) , 1-11
Abstract
Objective: Commonly measured clinical chemistry markers might be indicative of survival and disease progression in amyotrophic lateral sclerosis (ALS). Methods: In a cohort study of 270 ALS patients diagnosed from April 2014 to May 2021 in Stockholm, Sweden, we examined the link between 29 clinical chemistry markers at diagnosis and mortality risk at 6 months, 1 year, and 3 years after diagnosis. Summary variables from exploratory factor analysis (EFA) assessed the markers’ collective impact on survival. We integrated ALS functional rating scale-revised (ALSFRS-R) scores with survival data using a joint latent class model to identify patterns of functional decline. Multinomial logistic regression determined how the EFA-derived factors predicted the decline trajectories post-diagnosis. Results: Higher levels of total cholesterol, low-density lipoprotein cholesterol (LDL-C), apolipoprotein B, and albumin at diagnosis were linked to lower mortality in ALS patients, while increased neurofilament light chain (NfL), leukocyte count, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), and carbon dioxide (CO2) levels indicated higher mortality. The ‘Red blood cell profile’ factor, derived from EFA, emerged as a significant predictor of survival, independent of other prognostic indicators. The joint latent class model identified three distinct patient groups based on functional decline, with ‘Red blood cell profile’ suggesting a lower likelihood of being in the groups with slower progression. Conclusion: Clinical chemistry markers, including NfL, lipids, albumin, leukocyte count, MCV, MCH, CO2, and the ‘Red blood cell profile,’ were associated with ALS survival. As these markers represent broader bodily functions, integrating them in ALS patient care could improve disease management.Keywords
Funding Information
- European Research Council Starting Grant (MegaALS 802091)
- Centers for Disease Control and Prevention (R01TS000324-01-00)
- Swedish Research Council (2019-01088, 2023-02428)
- Björklunds Fund
- Ulla-Carin Lindquist Foundation
- NEURO Sweden
- Svenska Frimurarorden
- Karolinska Institute
This publication has 54 references indexed in Scilit:
- Lifestyle and medical conditions in relation to ALS risk and progression—an introduction to the Swedish ALSrisc StudyJournal of Neurology, 2024
- Association of blood lipids with onset and prognosis of amyotrophic lateral sclerosis: results from the ALS Swabia registryJournal of Neurology, 2023
- C‐reactive protein levels in patients with amyotrophic lateral sclerosis: A systematic reviewBrain and Behavior, 2022
- Decreased serum creatinine levels predict short survival in amyotrophic lateral sclerosisAnnals of Clinical and Translational Neurology, 2021
- Effect of High‐Caloric Nutrition on Survival in Amyotrophic Lateral SclerosisAnnals of Neurology, 2019
- Changes in routine laboratory tests and survival in amyotrophic lateral sclerosisNeurological Sciences, 2017
- Amyotrophic Lateral Sclerosis Outcome Measures and the Role of Albumin and CreatinineJAMA Neurology, 2014
- Novel insights into the pleiotropic effects of human serum albumin in health and diseaseBiochimica et Biophysica Acta (BBA) - General Subjects, 2013
- Multiple imputation using chained equations: Issues and guidance for practiceStatistics in Medicine, 2010
- Oxidative stress in ALS: A mechanism of neurodegeneration and a therapeutic targetBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2006